直腸診触知不能のPSA上昇例及びStage A前立腺癌におけるPSA, PSA densityの検討
スポンサーリンク
概要
- 論文の詳細を見る
直腸診触知不能のPSA上昇例及びstage A前立腺癌での癌検出率について,PSA,PSA density(PSAD)の比較検討を行い,更に前立腺肥大症と病期A前立腺癌のPSA transition zone(PSA-TZ)についても検討した.その結果,前立腺癌検出においてPSADをPSAと併用することは前立腺肥大症に対しての不必要な生検を回避するという点でPSA単独よりも有用と考えられた.又,PSAがgray zoneであれば,PSA-TZ値が前立腺肥大症とstage A前立腺癌の鑑別に有用となる可能性が考えられたWe compared the usefulness of PSA and PSA density (PSAD) in diagnosing prostate cancer in 102 men who had a PSA value higher than 4.0 ng/ml and normal digital rectal examination and who had undergone transrectal ultrasonography-guided systematic sextant biopsies of the prostate between August 1996 and October 1999. In addition, for a group of 53 patients who underwent retropubic simple prostatectomy, PSA, PSAD and PSA transition zone (PSA-TZ) examination results for those with stage A prostate cancer were compared with the results for those with benign prostatic hyperplasia (BPH). Of the former 102 men, 20 (19.6%) had prostate cancer. There was no significant difference in mean PSA level between patients with negative and those with positive biopsy results (mean 9.3 and 11.8, respectively, p = 0.295), but the mean PSAD of patients with positive biopsy results was significantly higher than that of those with negative results (mean 0.55 and 0.29, respectively, p = 0.0007). Of the 53 men who underwent retropubic simple prostatectomy, 10 (18.9%) were diagnosed with stage A prostate cancer. There was no significant difference in mean PSA, PSAD and PSA-TZ examination results between patients with BPH and those with stage A prostate cancer. For all 102 patients and for 71 patients with PSA levels of 4.1-10.0 ng/ml, a PSAD cutoff value of 0.1 reduced the number of biopsies 15.7% (16 of 102 cases), and 22.5% (16 of 71 cases), respectively. These results suggest that by measurement of PSAD some patients with benign disease could be spared a biopsy which would have been performed based on PSA results alone.
著者
関連論文
- PP-078 新規軟部肉腫転移関連遺伝子C7059の前立腺癌における機能解析(前立腺/基礎2,一般演題ポスター,第97回日本泌尿器科学会総会)
- 腎盂尿管癌の臨床的検討
- PP2-027 Kock pouchおよびileal neobladderにおけるハンモック尿管回腸吻合術の長期成績(一般演題(ポスター))
- PP-212 cDNA microarrayを用いた尿路上皮癌化学療法感受性予測因子同定の試み(尿路上皮腫瘍/基礎,一般演題ポスター,第96回日本泌尿器科学会総会)
- APP-027 尿路移行上皮癌におけるtriptolideを用いた癌特異的p21 target therapy(尿路上皮腫瘍・精巣腫瘍/基礎,総会賞応募ポスター,第96回日本泌尿器科学会総会)
- 腎炎症性偽腫瘍の1例
- 直腸診触知不能のPSA上昇例及びStage A前立腺癌におけるPSA, PSA densityの検討
- 同側腎無形成を伴った精嚢嚢胞の1例
- 長期経過観察しえた尿膜管癌5例の臨床的検討
- 局所浸潤性膀胱癌に対するCOMPA動注化学療法の検討。
- 根治的前立腺全摘術施行例における術前術後の病理組織学的検討
- Urinary"Urge Syndrome"に対するIPD^の臨床効果 : 尿中Interleukin-6(IL-6)濃度と末梢血免疫担当細胞からみた免疫学的検討
- 巨大な腸腰筋膿瘍の1例
- 膀胱Nephrogenic adenomaの3例
- 腎盂尿管癌の臨床的検討
- OP-114 膜温存体腔鏡下前立腺全摘除術におけるpositive surgical marginの検討(体腔鏡/前立腺,一般演題口演,第99回日本泌尿器科学会総会)
- APP-046 術前のretrograde leak point pressureは腹腔鏡下前立腺全摘除術後の尿禁制予測の指標となりうる(総会賞応募ポスター,第99回日本泌尿器科学会総会)
- OP-100 Homemade single-port deviceを用いた肝挙上用追加ポートを必要としないlaparoendoscopic single-site right adrenalectomyの経験(体腔鏡/副腎・腎・尿管・腹部,一般演題口演,第99回日本泌尿器科学会総会)